This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Mary Ellen Kosman, PhD

JAMA. 1979;242(26):2876-2878.

Abstract
Ticrynafen is an orally administered diuretic that is similar to the thiazides in its therapeutic actions, but, unlike the thiazides, it increases urate excretion and lowers serum uric acid levels. Ticrynafen is useful in the treatment of hypertension and in selected cases of chronic congestive heart failure. At present, it appears to be indicated primarily in patients with these disorders who have a history of gout. Patients who are currently receiving a thiazide should not have their therapy arbitrarily changed to ticrynafen because of asymptomatic hyperuricemia.

(JAMA 242:2876-2878, 1979)

Author Affiliations
From the Department of Drugs, American Medical Association, Chicago.

Footnotes
Reprint requests to Department of Drugs, American Medical Association, 535 N Dearborn St, Chicago, IL 60610 (Dr Kosman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The management of hyperuricemia and gout in patients with heart failure
Spieker et al.
Eur J Heart Fail 2002;4:403-410.
FULL TEXT